Furthermore, differences in IC50 scores of immunosuppressant-related genes and common chemotherapy drugs were observed between MAP7D3 high and low expression groups, suggesting a crucial role of MAP7D3 in PRAD immunotherapy and chemotherapy. The gene discussed is MAP7D3; the disease is prostate adenocarcinoma.